Quantcast
Home > Quotes > TSRO

TESARO, Inc. Common Stock (TSRO) Quote & Summary Data

TSRO 
$74.49
*  
0.18
0.24%
Get TSRO Alerts
*Delayed - data as of Dec. 13, 2018  -  Find a broker to begin trading TSRO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 74.25 / $ 74.58
1 Year Target
75
Today's High / Low
$ 74.50 / $ 74.1405
Share Volume
3,665,864
50 Day Avg. Daily Volume
3,924,319
Previous Close
$ 74.31
52 Week High / Low
$ 85 / $ 23.41
Market Cap
4,101,969,658
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -11.86
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.72

Intraday Chart

Shares Traded

Share Volume:
3,665,864
50 Day Avg. Daily Volume:
3,924,319

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -11.86

Trading Range

The current last sale of $74.49 is 218.20% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 74.50 $ 85
 Low: $ 74.1405 $ 23.41

ETFs with TSRO as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
3.15% SPDR Series Trust SPDR S&P Biotech ETF (XBI) -20.05 (-20.02%)
2.76% iShares U.S. Pharmaceutical ETF (IHE) -3.19 (-2.02%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a commercial-stage biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. Our primary focus is to develop treatments for solid tumors using various approaches, including small molecules and immuno-oncology antibodies, as monotherapies or in combinations. We have in-licensed and are developing several oncology-related product candidates, and we have entered into several research collaborations with third parties for the discovery of new candidates. We have also entered into arrangements with other companies for the development and commercialization of certain of our product candidates in specific indications and/or geographies. To date, we have received regulatory approvals for the following products, which are currently marketed and sold in the U.S. and in certain countries in Europe: ยท The U.S.  ... More ...  


Risk Grade

Where does TSRO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 74.30
Open Date:
Dec. 13, 2018
Close Price:
$ 74.49
Close Date:
Dec. 13, 2018

Consensus Recommendation

Analyst Info